{"name": "WILEX",
 "permalink": "wilex",
 "crunchbase_url": "http://www.crunchbase.com/company/wilex",
 "homepage_url": "http://www.wilex.de/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1997,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "investors@wilex.com",
 "phone_number": "+49 (0)89 41 31 38 0",
 "description": "",
 "created_at": "Mon Jun 14 07:07:28 UTC 2010",
 "updated_at": "Wed Jul 21 01:35:44 UTC 2010",
 "overview": "\u003Cp\u003EWILEX AG, a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company\u00e2\u20ac\u2122s products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       59],
      "assets/images/resized/0009/0484/90484v1-max-150x150.png"],
     [[170,
       67],
      "assets/images/resized/0009/0484/90484v1-max-250x250.png"],
     [[170,
       67],
      "assets/images/resized/0009/0484/90484v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman \u0026 CEO",
    "person":
     {"first_name": "Olaf",
      "last_name": "G Wilhelm",
      "permalink": "olaf-g-wilhelm",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Peter",
      "last_name": "Llewellyn-Davies",
      "permalink": "peter-llewellyn-davies",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$27.1M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.wilex.de/News/2010/230310.htm",
    "source_description": "WILEX AG secures financing up to EUR 20 million through an equity line",
    "raised_amount": 27070000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 3,
    "funded_day": 23,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Yorkville Advisors",
         "permalink": "yorkville-advisors",
         "image":
          {"available_sizes":
            [[[150,
               94],
              "assets/images/resized/0006/0873/60873v1-max-150x150.png"],
             [[228,
               144],
              "assets/images/resized/0006/0873/60873v1-max-250x250.png"],
             [[228,
               144],
              "assets/images/resized/0006/0873/60873v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Grillparzerstr. 10 ",
    "address2": "",
    "zip_code": "81675 ",
    "city": "Munich ",
    "state_code": null,
    "country_code": "DEU",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "XTRA:WL6"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}